Acquired Platelet Dysfunction in 109 Patients From a Tertiary Care Referral Hospital

作者：Sharma Prashant; Kar Rakhee; Bhargava Rahul; Ranjan Ravi; Mishra Pravas Chandra; Saxena Renu^*

来源：Clinical and Applied Thrombosis/Hemostasis, 2011, 17(1): 88-93.

DOI：10.1177/1076029610379397

• acquired platelet dysfunction
• bleeding
• drug-induced disorder
• light-transmission platelet aggregometry
• myeloproliferative neoplasm
• plasma cell dyscrasia
• thrombosis

Background: Acquired platelet function defects (PFDs) remain poorly characterized, underrecognized, and therefore understudied. Patients/Methods: Clinical and laboratory records of 109 patients with acquired PFDs diagnosed over 5 years were analyzed. Screening studies (platelet count, prothrombin time, activated partial thromboplastin time, and thrombin time), template bleeding time, platelet factor 3 (PF-3) availability test, light-transmission aggregometry, and further testing as indicated were performed. Results: 64 patients had mild and 26 had major bleeding. In all, 15 were referred for preoperative testing, whereas 4 had thrombotic events. Causes and associations of PFDs were drug-induced (34), idiopathic (34), hematopoietic neoplasms (15; myeloma 4, Waldenstrom macroglobulinemia 2, chronic myeloid leukemia 4, essential thrombocythaemia 3, and primary myelofibrosis and chronic lymphocytic leukemia 1 each), chronic liver disease (4), postcardiac surgery (2), uremia (2), and thalassemia major (7). Miscellaneous disorders comprised the rest. Conclusions: Acquired PFDs span a wide range of disease settings. Systematic, sequential laboratory testing identifies patterns of dysfunction, excludes inherited disorders, and streamlines management.

• 出版日期2011-2
• 单位河北医科大学